Jihao Zhou, M.D., Ph.D.

Jihao Zhou, M.D., Ph.D., is the Senior Vice President and Head of Biometrics at BlossomHill Therapeutics, where he oversees biostatistics, statistical programming, and clinical data sciences. Dr. Zhou has more than two decades of experience in clinical drug development, with a primary focus on biometrics. Prior to BlossomHill, Dr. Zhou held a variety of technical and leadership roles of increasing responsibility at Autobahn Therapeutics, AnaptysBio, Urovant, Allergan, and Pfizer. Throughout these tenures, he and his teams made significant contributions to the development and approval of major pharmaceutical products, including Pfizer’s blockbuster oncology drug sunitinib (SUTENT®), Allergan’s botulinum toxin (BOTOX®) for therapeutic indications, and Urovant’s vibegron (GEMTESA®) for overactive bladder (OAB).   

An innovator in clinical drug development, Dr. Zhou is an inventor and co-inventor on patent applications across multiple medical fields. He earned his Doctor of Medicine from Peking Union Medical College in Beijing, completed a postdoctoral fellowship at the University of Münster in Germany, and received a Ph.D. in biostatistics from the University of Michigan, Ann Arbor.